• About us
• Contact

Advertisement

Organisation › Details

Swedish Orphan Biovitrum Manufacturing AB

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. *

 

	Start	2010-01-14 renamed date ca
	Group	Swedish Orphan Biovitrum (Sobi) (Group)
	Predecessor	Swedish Orphan International Manufacturing AB
	Industry	DRUGS, ORPHAN
	Region	Umeå
	Country	Sweden
	Street	48 Tvistevägen
	City	90719 Umeå
	Tel	+46-90-172250
		Address record changed: 2021-10-26
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Swedish Orphan Biovitrum (Sobi) (Group)

• [1] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
• [2] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
• [3] Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase"....
• [4] AstraZeneca plc. (8/22/19). "Press Release: AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi"....
• [5] Swedish Orphan Biovitrum AB. (10/24/17). "Press Release: Sobi Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel"....
• [6] Swedish Orphan Biovitrum AB. (10/6/17). "Press Release: Norbert Oppitz Joins Sobi as New Senior Vice President, Specialty Care"....
• [7] PCI Biotech Holding ASA. (8/23/17). "Press Release: PCI Biotech Appoints Dr Hans Olivecrona as Chief Medical Officer". Oslo....
• [8] Swedish Orphan Biovitrum AB. (5/4/17). "Press Release: Guido Oelkers Appointed President and CEO at Sobi"....
• [9] Swedish Orphan Biovitrum AB. (5/3/17). "Press Release: Sobi Opens Office in Greece"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.